With the inevitable progression of the disease, patients often require more intensive therapy, which prior to the development of cystic fibrosis transmembrane conductance regulator (CFTR) drugs, only targeted the symptoms. 8 In the clinical setting, the most common methods to measure CFTR function are the assessments of sweat chloride concentration and nasal potential difference. 9 Sweat chloride is a promising biomarker, as sweat glands do not seem to be subjected to the secondary damage from CF abnormalities, which can occur at an early age (unlike, i.e., lung and gastrointestinal tract tissue). Notably, sweat chloride concentration has been proposed as an index of CFTR function. 10 This suggestion arises from the assumption that greater residual CFTR function leads to lower sweat chloride concentrations, as well as protection against severe lung disease. However, sweat chloride concentration alone does not necessarily predict a milder pulmonary course of the disease. 10 Clinical manifestations of CF include chronic lung infection and inflammation with the loss of lung function that eventually results in respiratory failure. 4 Thick mucus accumulation in the lung promotes bacterial infections. 4, 7 Major pathogens in CF lungs commonly include
Pseudomonas aeruginosa followed by Haemophilus influenzae, Staphylococcus aureus, Burkholderia pseudomallei, and Stenotrophomonas maltophilia. 4, 7, 11 Thick mucus also obstructs the pancreatic duct, eventually leading to complete closure by scar tissue, which results in exocrine pancreatic insufficiency. 4, 12, 13 Insufficient secretion of pancreatic enzymes leads to malabsorption of fats and protein that results in deficiencies of fat-soluble vitamins (i.e., A, D, E, and K), leading to cachexia that predisposes patients to infection. 4 In general, patients with CF with pancreatic sufficiency are associated with milder expression of the CF phenotype. 1, 3, 12 One consequence of pancreatic insufficiency, namely, distal intestinal obstructive disease, is caused by partial or complete bowel obstruction caused by inspissated feces. 4 This condition necessitates surgery in 10% of newborns with CF. 13 Gastrointestinal reflux disease or rectal prolapses are also more common in patients with CF than in the general population.
At present, there is no cure for CF. Due to the complex disease manifestations and multiorgan involvement, patient management usually requires a large number of medications for symptomatic treatment of respiratory infections, inflammation, the clearance of mucus, and nutritional maintainance. 1, 4 In recent years, medical and technological improvements like early diagnosis, specialist care, advanced treatment methods, and lung transplants have resulted in an increase in median survival age to now $37.5 years in total (in the US). This is a marked improvement from the 1980s, when the median survival age was $20 years. 4 This shift furthermore impacts socioeconomic aspects such as independent adults with this lethal disease entering the workforce or wishing to start their own families.
Notwithstanding, there is still a high unmet medical need for effective treatment that targets the underlying mechanism of the diseased state itself. 20 The progressive nature of CF combined with the lifelong healthcare costs are major factors in favor for the development of novel CF therapeutics that modulate CFTR function. 18 lumacaftor/ivacaftor, the novel lumacaftor-ivacaftor combination, is the first CF therapeutic that actually treats the disease itself as opposed to only managing the symptoms. Excitingly, this new therapeutic potentially represents the "magic bullet" patients with CF and respiratory clinicians have been waiting for. Worryingly, a number of conflicting reports have emerged that overshadow the clinical efficacy of this purported wonder drug. 21, 22 Can lumacaftor/ivacaftor live up to its promise of allowing patients with CF to finally "catch a breath"? This review surveys the current clinical and preclinical knowledge-base on lumacaftor/ivacaftor, and provides a critical point of view of the benefits and potential caveats of this revolutionary new CFTR corrector-modulator combination.
MODE OF ACTION
An understanding of the mode of action of lumacaftor/ivacaftor necessitates the background into the biology and mechanism of the CF disease state itself.
CF is caused by mutations in the gene that encodes the CFTR protein, which is expressed in epithelial cells of various tissues, including the lung. 3 The full-length CFTR protein is a multidomain membrane protein consisting of two membrane spanning domain (MSD1&2) and two nucleotide binding domains (NBD1&2) linked together by a phosphorylation regulated (R) domain ( Figure 1A) . 23 The MSD forms an anion-selective pore and the dimerized NBDs mediate the adenosine triphosphate (ATP)-binding, -hydrolysis, and ATP-dependent gating by the phosphorylation of the CFTR protein. 23 CFTR function is regulated by the cyclic adenosine monophosphate (cAMP)-dependent protein kinase A. The CFTR functions to conduct hydrochloride across the cytoplasmic membrane. 24, 25 A deficiency in bicarbonate secretion results in poor solubility of luminal mucus, leading to the production of abnormal mucus secretion that damages the lungs, liver, pancreas, and intestine resulting in multiorgan failure. 4, 5, 13 Furthermore, due to a mutation in the CFTR, the majority of men with CF suffer from associated congenital bilateral absence of the vas deferens, which results in obstructive azoospermia. 26 One in 22 people of European descent carry one gene for CF, making it one of the most common autosomal recessive genetic diseases. 3 More than 1,900 CFTR protein mutations have been identified and are categorized into functional classes I, II, III, IV, V, and VI ( Figure 1B) . 1, 3 Broadly speaking, the class I, II, and III mutations lead to the classic CF phenotype, with pancreatic insufficiency and a nonfunctional CFTR; while IV, V, and VI mutations produce a partially functional CFTR and are associated with a milder form of the disease. 1, 3, 13 Class I mutations result in the expression of a defective CFTR with a complete loss of function. 13 The most common mutation found in 70% of patients with CF (Caucasians of European descent) is the class II F508 deletion. Class III mutations (i.e., G551D) result in defective regulation of channel opening. 13, 27 The G551D mutation produces a CFTR protein that is localized on the epithelial membrane but fails to open. 28 The G551D-CFTR is a missense mutation targeted by Kalydeco and is seen in $4% of patients with CF and is the third most common mutation found in class III. 3 A clinical study conducted by Vertex convincingly demonstrated the clinical efficacy of ivacaftor in a cohort of 167 G551D-CFTR CF patients. 16, 29 Patients received 150 mg ivacaftor or placebo every 12 h with fat-containing food for 48 weeks. The ivacaftor treatment group displayed a 10.6% improvement in ppFEV1 in patients !12 years (P < 0.0001) and 12.5% (P < 0.0001) in patients aged 6-11 years compared to placebo that continued through a 48-week period.
The class II mutation causes aberrant processing of the CFTR protein, which leads to either its trafficking to the incorrect location or the presentation of the nonfunctional mature glycoform of CFTR ( Figure 1B) . 13 The F508del mutation is by far the most common mutation in the population with CF, with an overall prevalence of 70% and about 50% homozygous patients, 16 positioning itself as a major target for CFTR corrector/modulator therapeutics. 28 This mutation produces a severe defect in the processing and trafficking of CFTR, resulting in little to no CFTR protein presentation on the cell surface, 16, 25, [30] [31] [32] [33] [34] [35] [36] and additionally leads to abnormal opening of the channel in the limited amounts of CFTR that actually make it to the cell surface. 28 Class IV mutations result in defective ion conductance by the CFTR. 13 Class V mutations marginally decrease the amount of functional CFTR at the cell surface and class VI mutations impact the stability of the CFTR at the cell surface. [37] [38] [39] [40] Notwithstanding, patients with class V and VI mutations still retain some functional CFTR expression ( Figure 1B) .
Serendipitously, the concept for the development of CFTR modulators originated from background research on the class II F508del-CFTR mutation. The F508del mutation in NBD1 leads to a decrease in the thermostability of the CFTR. 23, 41, 42 Moreover, the F508del mutation perturbs the native interactions between NBD1 and the coupling helix of MSD2. 23 The breakthrough finding was that misfolding of the defective F508del-CFTR could be corrected by lowering the temperature (<308C) or by employing chemical chaperones (e.g., glycerol). [43] [44] [45] [46] [47] [48] For the first time, this indicated that defective CFTR function could be restored; this in turn led to extensive efforts by Vertex to identify small-molecule CFTR modulators. [43] [44] [45] [46] [47] [48] Mechanistically, CFTR modulators fall into three classes: 1) suppressors that prevent premature termination of protein synthesis (i.e., ataluren); 2) correctors that partially correct folding and processing defects (i.e., lumacaftor); and 3) potentiators that increase channel gating and conductance (i.e., ivacaftor). Eckford et al. 49 were the first to report that ivacaftor binds directly to the CFTR protein, causing CFTR channel opening via a nonconventional ATP-independent mechanism. 49 In CHO (Chinese hamster ovary) and human CFPAC-1 (human Caucasian pancreatic adenocarcinoma) cell culture models, lumacaftor has been shown to increase the amount of functional CFTR present at the cell surface by $34%. 50, 51 Van Goor et al. 32 showed that in cultured human bronchial epithelial cells, lumacaftor improved F508del-CFTR trafficking to the cell surface and furthermore enhanced chloride secretion up to 14%. 32 Furthermore, Ren et al. 50 proved that lumacaftor stabilized the F508del-CFTR N-terminal domain (the MSD-1 region) and partially restored the function. Coincidently, Kopeikin et al. 51 have shown that the main effect of ivacaftor on F508del-CFTR is to increase the ATP-dependent opening rate of the channel. The authors purport that this results from the destabilization of the closed-state, thereby shifting the balance towards the open state ( Figure 2) . 51 On a purely mechanistic level, there is substantial evidence in favor of combining the CFTR potentiator ivacaftor with the CFTR corrector lumacaftor. However, as will be outlined in the following discussion, on a pharmacokinetic level the combination of ivacaftor with lumacaftor may not be a marriage made in heaven.
LUMACAFTOR/IVACAFTOR "THE PROMISED LAND OF CLINICAL EFFICACY"
The three pillars of CF therapy are 1) maintaining lung function, 2) reducing the frequency of pulmonary exacerbations, and finally 3) improving nutritional status. 16, 52 Ivacaftor (VX-770) is the first FDA-approved CFTR potentiator. [53] [54] [55] Ivacaftor functions as a G551D-CFTR potentiator producing an increased channel opening probability to enhance chloride influx. 49, 56 Although Vertex's first of its kind CFTR potentiator drug Kalydeco (ivacaftor) represents a major breakthrough in CF therapy, its target patient collective is limited to around 4% of patients with CF Figure 2 Mutant F508del CFTR channel after prolonged lumacaftor/ivacaftor treatment. Left, lumacaftor/ivacaftor therapy improves long-term CFTR function by acting to enhance the trafficking of CFTR to the cell surface and enhancing Cl-influx intracellularly. Right, alternatively, prolonged lumacaftor/ ivacaftor therapy could cause destabilization and accelerated turnover of CFTR, resulting in less functional CFTR being presented on the cell surface.
(G551D mutation) (glycine (G) in position 551 is replaced by aspartic acid (D)). 3, 21 Additionally, ivacaftor was later approved for other gating mutations such as G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. 57 To solve this limitation, Vertex developed the novel correctorpotentiator combination lumacaftor/ivacaftor (lumacaftor-ivacaftor), which targets the vast majority of CF patients carrying the homozygous F508del-CFTR. The F508del is an in-frame deletion of the CFTR gene, which results in the loss of phenylalanine (F) at position 508. 25, [30] [31] [32] [33] [34] [35] [36] Lumacaftor (VX-809) is a first of its kind CFTR corrector that facilitates processing and trafficking of the F508del-CFTR protein to increase the amount at the epithelial cell surface ( Table 1) . 16 This strategy combines a CFTR corrector that rescues F508del-CFTR to the cell surface with a potentiator that increases the channel gating open probability, 50 and effectively expands the treatment window to $28% of the CF population. 58 In the US alone, lumacaftor/ivacaftor now expands the patient collective from only 1,950 patients who were treatable with Kalydeco to 15,000 patients with homozygous F508del-CFTR mutation. 16, 25, [30] [31] [32] In the Vertex clinical phase III studies 103 and 104 (TRAFFIC and TRANSPORT) ( Table  2 ) involving 1,108 homozygous F508del-CFTR patients, lumacaftor/ivacaftor was shown to decrease sweat chloride secretion and increase ppFEV1 (percent predicted forced expiratory volume in 1 sec) over placebo. 16 According to Vertex's FDA briefing, lumacaftor/ivacaftor proved to be superior over placebo in 16, 59 Notably, the ppFEV1 was sustained over a 48-week period. 16, 50 Encouragingly, patients receiving lumacaftor/ivacaftor experienced less lung infections requiring hospitalization (-61% (P < 0.0001)) or intravenous (i.v.) antibiotics (-56% (P < 0.0001)). 16 
lumacaftor/ivacaftor phase II efficacy results
Lumacaftor by itself went into a phase II clinical study, where patients with CF with homozygous F508del-CFTR mutations were randomly assigned 25-200 mg/day lumacaftor for 4 weeks ( Table 2) . 43 The study findings revealed that lumacaftor produced a dose-dependent, rapid, and sustained reduction in sweat chloride levels (P 5 0.0013). The reduction in sweat chloride values was rapid and sustained, with changes seen within 7 days of lumacaftor therapy. The mean change from baseline in sweat chloride concentration (mmol/l) were 12.2 in the placebo group, -0.5 (25 mg), -3.7 (50 mg (95% confidence interval (CI) -7.1 to -0.28, P 5 0.03)), -2.3 (100 mg); and -6.6 (200 mg (95% CI -10.27 to -2.83, P 5 0.0008)). 20 However, the study did not show sufficient clinical benefit due to increased pulmonary exacerbation rates, and disappointing FEV1-scores (percentage changes relative from baseline FEV1: placebo 10.07, In further phase II trials, study 102 efficacy results reported by Boyle et al. 37 (Table 2) showed that lumacaftor/ivacaftor therapy was able to achieve an improvement in lung function (measured as FEV1) for a collective of 312 CF patients suffering from homozygous F508del-CFTR mutation (initial lung function 40-90% FEV1). 37, 60 In cohort 1 ( Table 2) , 62 homozygous F508del-CFTR patients received 200 mg lumacaftor once daily, combined with 150 or 250 mg doses of ivacaftor (twice daily). Both of these treatment groups showed a reduction of sweat chloride ($9.1 mmol/L (P < 0.001)) compared to placebo; however, no significant changes in FEV1 were observed. 60, 61 In cohorts 2 and 3, mean sweat chloride concentrations did not decrease significantly between day 28 and day 56 (cohort 2: P 5 0.889 (lumacaftor 200 mg once per day, ivacaftor 250 mg every 12 h); P 5 0.664 (lumacaftor 400 mg once per day, ivacaftor 250 mg every 12 h); P 5 0.218 (lumacaftor 600 mg once daily, ivacaftor 250 mg every 12 h) and cohort 3: P 5 0.544 (lumacaftor 400 mg-ivacaftor 250 mg every 12 h)); compared to baseline. However, in a preplanned secondary analysis, Boyle et al. observed that the total change in sweat chloride over the entire study period of 56 days decreased significantly in the lumacaftor 400 mg and the lumacaftor 600 mg group for 28 days followed by the addition of ivacaftor 250 mg for a further 28 days: -9.1 mmol/L (95% CI -13.3 to -4.9; P < 0.001; change from baseline) and -8.9 mmol/L (-13.1 to -4.7; P < 0.001 (change from baseline), respectively. For the patients from cohort 3 the total change in sweat chloride over the entire study period was -10.3 mmol/L (-16.7 to -4.0 P 5 0.002). These reductions were significant compared with placebo (-11.1, -18.5 to -3.7, P 5 0.00 (treatment vs. placebo)). 60 Most important, in cohort 2 patients treated with lumacaftor 600 mg once daily displayed an improvement in FEV1 (change from baseline) of 5.6% (P 5 0.013). 60 In cohort 3, FEV1 only improved during the combination period by 7.7% (P 5 0.003). These dose ranging studies suggest that lumacaftor should be dosed at a higher ratio to ivacaftor, which leads us to the phase III studies.
lumacaftor/ivacaftor phase III efficacy results
The multicenter phase III studies led by Wainwright et al. 58 and Boyle et al. 60 corroborated the phase II findings. 58 They conducted two phase III, randomized, double-blind, placebocontrolled studies to investigate the effectiveness of lumacaftor combined with ivacaftor in 1,108 patients with CF 12 years or older who had the homozygous F508del-CFTR mutation and an FEV1 of 40-90%. 58 In contrast to the phase II study, the patients were given a high dose of lumacaftor 600 mg once daily or 400 mg every 12 h in combination with ivacaftor 250 mg every 12 h for an extended duration of 24 weeks. 58 The nonplacebo patients displayed an increase in FEV1 within 15 days of the initiation of therapy that was sustained throughout 24 weeks. The reported findings in the New England Journal of Medicine showed a significant improvement of predicted FEV1 (change from baseline) in the lumacaftor-ivacaftor group over placebo (3.3% for the 600 mg once daily and 2.8% for the 400 mg twice daily, respectively (P < 0.001 for all groups)); less pulmonary exacerbations (39% fewer exacerbations in the 400 mg twice daily lumacaftor group compared to placebo (P < 0.001) and 30% fewer exacerbation in the 600 mg once daily lumacaftor group compared to placebo (P 5 0.001)). Similar to the phase II studies, the phase III study patients displayed an overall lower rate of hospitalization and/or the use of i.v. antibiotics.
58,61
PHARMACOKINETICS lumacaftor/ivacaftor is prescribed as an oral dose twice daily every 12 h in the form of a tablet (200 mg lumacaftor and 125 mg ivacaftor). 16, [32] [33] [34] [35] [36] After administration, lumacaftor and ivacaftor are absorbed in the gastrointestinal tract and exhibit peak plasma concentrations (T max ) in $3-6 h and $4 h, respectively. 29 The systemic exposure of lumacaftor is $2-fold higher in healthy individuals compared to patients with CF ( Table 3) . 59 The difference in the area under the curve (AUC) might be attributed to absorption difficulties in patients with CF due to deficiencies in pancreatic enzymes, impaired bowel movement, or thick mucus accumulation. However, experimental data are needed to validate these postulates. The exposure of ivacaftor in healthy or patients with CF is similar. 29 The exposure of lumacaftor and ivacaftor is Table 3 Continued on next page REVIEWS increased when given with high-fat-containing food. 29 After a single dose with high-fat-containing food, lumacaftor exposure was $2-fold higher and ivacaftor exposure was $3-fold higher compared to those administered on a fasting stomach ( Table 3) . 59 It is a common phenomenon that the oral absorption of lipophilic drugs is improved by dietary fats, which leads us to the postulate that the oral absorption (the oral bioavailability of lumacaftor/ivacaftor ranging from 30-100%) 29 of lumacaftor/ ivacaftor could be optimized via a lipid-based formulation. 16, 29, 53 Presently, there is very little information regarding the peak and steady-state plasma concentrations of Kalydeco or lumacaftor/ ivacaftor. Schneider et al. recently published a high-performance liquid chromatography (HPLC) liquid chromatography mass spectrometry (LC/MS) method for the monitoring of exposureresponse relationships of ivacaftor and lumacaftor. 62 Given the noted metabolism of ivacaftor and lumacaftor, monitoring of exposure-response relationships is requisite to achieve optimized dosage regimens for Kalydeco or lumacaftor/ivacaftor therapy. Hence, there remains the question of whether current dosage regimens are achieving optimal exposure levels and/or if overdosing is an issue.
Ivacaftor and lumacaftor are both very hydrophobic drugs and as such are $99% bound to plasma proteins, which significantly limits the free (active) drug concentration. 1 Ivacaftor is highly bound to human serum albumin (HSA) and a1-acid glycoprotein (AGP). 1 Similarly, lumacaftor preferentially binds to HSA. 29, 59 Schneider et al. investigated the impact of coadministered CF drugs on the plasma protein binding of ivacaftor. 1 Using surface plasmon resonance and fluorimetric binding assays that measure the displacement of site-selective probes, they showed that interactions between ivacaftor are to be expected with ducosate, montelukast, ibuprofen, dicloxacillin, omeprazole, and loratadine due to their ability to strongly compete for the ivacaftor binding sites on HSA and AGP. The half-life of lumacaftor administered as lumacaftor/ivacaftor is about 26 h in patients with CF. The half-life of ivacaftor administered as Kalydeco is 12 h and $9 h when administered as lumacaftor/ ivacaftor. 29, 59 Due to high plasma protein binding there is a strong possibility that coadministered CF drugs could compete with ivacaftor or lumacaftor for the same plasma protein binding sites and impact the free drug concentration. This in turn could lead to variable free drug plasma concentrations and thereby impact therapeutic outcomes. 1 Similarly, the shorter half-life of ivacaftor when administered as lumacaftor/ivacaftor may be due to the displacement from its plasma protein binding sites by lumacaftor, which in turn leads to increased free drug and clearance. Our group has reported that such drug-drug interactions between ivacaftor and other CF drugs can be expected with docusate, montelukast, ibuprofen, dicloxacillin, omeprazole, and loratadine. Ideally, Kalydeco and lumacaftor/ivacaftor should be administered in a staggered dosage regimen with these CF drugs to maximize free drug concentrations and clinical efficacy. 1 Ivacaftor is heavily metabolized in humans, primarily by CYP3A4 into 11 metabolites found in bile, urine, plasma, and feces. 53, 59 Ivacaftor is primarily metabolized into active hydroxymethyl-ivacaftor (M1) and inactive ivacaftor-carboxylate (M6) by oxidation ( Table 1) . 53, 59 A disconcerting aspect of the metabolism of lumacaftor/ivacaftor is the potentially complex interactions between lumacaftor and ivacaftor themselves and with the supplementing medications to treat the symptoms of this multisystem disease ( Table 3) . 52 Notably, strong CYP3A4 inhibitors such as clarithromycin or -azole antifungals have been reported to increase exposure of ivacaftor. 16 The product information insert states that in the first week of initiating lumacaftor/ivacaftor or Kalydeco therapy in conjunction with these drugs, half of the dose of ivacaftor/lumacaftor is recommended ( Table 3) . 59 Similarly, the concomitant use of strong CYP3A4 inducers such as rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, and St John's Wort (Hypericum perforatum) are not recommended, as the exposure of ivacaftor is decreased by $57%. 59 Lumacaftor is not heavily metabolized, with the majority being excreted unchanged in the feces. 16, 29 The $10% of lumacaftor that is metabolized occurs via oxidation and glucuronidation. 29 In the FDA and EMA reports for lumacaftor/ ivacaftor, Vertex mentions lumacaftor itself is an inducer of the cytochrome P450 drug-metabolizing enzymes. 16, 29 Paradoxically, ivacaftor is a substrate of cytochrome P450 3A4 (CYP3A4), which leads us to another potential antagonistic drug-drug interaction between the actual components of lumacaftor/ivacaftor themselves (i.e., lumacaftor vs. ivacaftor). 29, 59 To this end, we have found that the steady-state plasma concentration of ivacaftor in patients receiving lumacaftor/ivacaftor therapy is significantly lower than the levels we measured in patients receiving Kalydeco therapy. 62 
SIDE EFFECTS
In general, oral administration of lumacaftor/ivacaftor showed an acceptable tolerability profile when added to the standard therapy of patients with CF aged !12 years in the 24-week TRAFFIC and TRANSPORT studies. 58 However, to date the 120-week extension of these trials, called the PROGRESS study, is still ongoing. Aside from the benefits of lumacaftor/ivacaftor, it is also essential to examine the other side of the coin, its potential caveats. Ironically, the major adverse effects reported for patients undergoing lumacaftor/ ivacaftor therapy vs. placebo were dyspnea (14%:7.8%) and respiratory chest tightness (9.8%:5.9%). 16, 29, 59 Diarrhea, nausea, and upper respiratory tract infections have also been reported as adverse effects. 16, 59 Notwithstanding, Vertex suggests that most respiratory adverse effects resolve within the first few weeks of treatment. 16, 59 Additionally, elevation of liver enzymes and hepatobiliary disorders were reported in some patients compared to placebo (0.9%). 16 This could restrict lumacaftor/ivacaftor treatment, as up to 35% of patients with CF suffer from liver disease, a known clinical manifestation as a result of CFTR dysfunction in their biliary tract cells. 15, 16, [63] [64] [65] [66] Coincidently, Vertex's pooled phase II studies 103 and 104 were discontinued due to the patients exhibiting elevated liver transaminases (0.5%) and respiratory events (0.7%). 16 If the benefits of therapy outweigh the risks, lumacaftor/ivacaftor could be used carefully at a lower dosage and, importantly, with close monitoring in patients with advanced liver disease. 59 Thus, liver function monitoring is recommended prior to and during the course of lumacaftor/ivacaftor therapy.
Due to their lipophilicity, ivacaftor and lumacaftor could potentially cross the blood-brain barrier. Pharmacodynamic studies in rats have shown that ivacaftor functions as an inhibitor of the monoamine transporter and binds serotonin 5-HT2C receptors, 16 suggesting that Kalydeco and lumacaftor/ivacaftor could possess neuropharmacological activity.
To date, no adverse data for lumacaftor/ivacaftor in pregnant women has been reported; currently lumacaftor/ivacaftor is listed as a pregnancy category "B" drug that requires additional human trials. 61, 67 Kaminski et al. 68 were the first to report a successful uncomplicated pregnancy during Kalydeco therapy for a single patient with CF. 68 However, breastfeeding mothers should remain cautious, as both ivacaftor and lumacaftor have been detected in the milk of lactating rats. 61, 67 A beneficial side effect of ivacaftor is its antimicrobial activity. [69] [70] [71] Schneider et al. have shown synergistic antibacterial activity of ivacaftor in combination with polymyxin B against a panel of polymyxin-resistant Gram-negative pathogens that commonly colonize the lungs of patients with CF, including strains that were resistant to the quinolone antibiotic ciprofloxacin, which is structurally related to ivacaftor. 69, 70 As polymyxins (in particular colistin) are commonly used in patients with CF for treatment of lung infections caused by multidrug-resistant P. aeruginosa, such a synergistic killing effect plays a key role in minimizing any potential resistance to polymyxins. 70 
IVACAFTOR VS. LUMACAFTOR
Although the aforementioned TRANSPORT and TRAFFIC clinical studies confirmed that lumacaftor/ivacaftor therapy improves F508del-CFTR function from Day 1 to Day 56 of therapy, the reasons for the discouraging long-term results (>24 weeks) were not obvious from the available clinical data (TRANSPORT and TRAFFIC studies for long-term efficacy and safety are still ongoing). Recently, evidence has emerged from a number of independent laboratories suggesting that prolonged exposure to ivacaftor counteracts the corrector function of lumacaftor by destabilizing the lumacaftor-rescued mature glycoform of F508del-CFTR. 21, 22, 72 Such inhibitory interactions are especially concerning, given that lumacaftor only partially restores (11-15%) F508del-CFTR surface expression. 21, 22 The in vitro studies by Gentzsch et al. 22, 43 suggested that chronic administration of ivacaftor caused a dose-dependent reversal of lumacaftor-mediated CFTR correction in homozygous F508del human primary bronchial epithelial cells. They reported that in cells chronically treated with 5 lM lumacaftor, acute exposure to ivacaftor (5 lM) resulted in an increase of CFTR-mediated ion transport within minutes. 22 Whereas chronic treatment (24-48 h) of lumacaftor rescued cells with 5 lM ivacaftor resulted in a decrease in channel conductance. 22 This result reflected the destabilization of corrected DF508 CFTR by ivacaftor, dramatically increasing its turnover rate. Chronic ivacaftor treatment furthermore reduced mature wildtype CFTR levels and function. These findings demonstrate that chronic treatment with CFTR potentiators and correctors may have unexpected effects that cannot be predicted from short-term studies. Furthermore, it was demonstrated that the CFTR-mediated short-circuit current increases after addition of ivacaftor to corrector-rescued F508del-CFTR, albeit this effect was transient. 22 These findings may be an indicator of a rapidly decreasing quantity of functional protein at the apical membrane. 22 They also showed that the loss of corrected-rescued function of F508del-CFTR treated with lumacaftor in combination with ivacaftor was reflected in reduced chloride secretion responses. 22 In their western blot the amount of mature F508del-CFTR was actually diminished, and instead the F508del-CFTR protein only appeared as an immature band B. 22 Therefore, it is essential that we gain further knowledge of the interaction and interference between CFTR potentiators and CFTR correctors.
Another recent study by Veit et al. 21 indicated that ivacaftor reduces the correction efficacy of lumacaftor. Their results indicated that ivacaftor destabilizes the native CFTR protein in immortalized and primary human respiratory epithelia. 21 The authors purport that destabilization is caused by ivacaftor itself, which could further play an essential role in the faulty assemblage of the CFTR protein. Furthermore, this implies that the lumacaftor rescued F508del-CFTR is still defective and not functionally equivalent to the native CFTR. 73 These findings show that chronic treatment with lumacaftor/ivacaftor may have unexpected long-term effects that are not predictable from the clinical studies.
COST VS. BENEFIT
Affordability is a key issue with lumacaftor/ivacaftor therapy. 28 As the price is supposed to be representative of the compensation Vertex would expect to cover their development costs (due the small patient collective), we would assume the price of Kalydeco to have gone down with the introduction of lumacaftor/ ivacaftor. 28 However, pricing for both drugs remains extraordinarily high, despite the low cost of goods (ivacaftor and lumacaftor are easily accessible synthetically and therefore the cost of development is presumably low). However, we must take into account the high development costs that would help justify the high price of these drugs. lumacaftor/ivacaftor treatment is estimated at $259,000 USD per year, which is lower than the established pricing of Kalydeco at $307,000 USD per year. 61, 74 Given the price differential, it would be more economically prudent for patients with G551D-CFTR to simply adopt lumacaftor/ivacaftor therapy. However, lumacaftor/ivacaftor has yet to be approved for patients with G551D-CFTR. Moreover, given that patients with G551D-CFTR express CFTR on the epithelial cell surface, this may not prove successful due to the increase in CFTR turnover rates reported with lumacaftor/ivacaftor therapy ( Figure 2) . 21, 22, 45 As patients are forced to take lumacaftor/ivacaftor or Kalydeco as a lifelong therapy, the impact on the healthcare budget is staggering. 40 In view of the modest clinical outcomes reported for lumacaftor/ivacaftor therapy, the cost vs. benefit becomes questionable.
PERSPECTIVE: CAN CF PATIENTS FINALLY CATCH A BREATH?
lumacaftor/ivacaftor represents a first-of-its-kind breakthrough CF treatment strategy. However, since its release a number of key questions remain unanswered. First and foremost, unlike the experience with Kalydeco, patients receiving lumacaftor/ivacaftor therapy displayed only modest improvements in lung function and pulmonary exacerbations. 16 Second, antagonistic drug-drug interactions could potentially limit lumacaftor/ivacaftor's clinical efficacy. 57 Despite these concerns, the long-term benefits of lumacaftor/ivacaftor require further assessment and we are all curiously awaiting the results of the ongoing long-term TRANSPORT and TRAFFIC studies for these two revolutionary CF drugs.
